Pharvaris (PHVS) reported Tuesday Q1 loss of 0.60 euros ($0.70) per diluted share, narrowing from a loss of 0.85 euros a year earlier.
Analysts polled by FactSet expected a loss of 0.71 euros.
Cash and cash equivalents were 247 million euros as of March 31. The company said a subsequent $132 million underwritten offering is expected to extend its cash runway into 2028.